Floatz Rating
CC46/100
Confidence
Indicative
Sponsor
Isarna Therapeutics GmbH
Modality
UNKNOWN
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
35Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00761280CT.gov Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anaplastic Astrocytoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trabedersen (this asset) | Isarna Therapeutics GmbH | P3 | CC · 46 |
| Irinotecan | City of Hope Medical Center | P2/3 | BB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
| (+)-Vincristine | Novartis Pharmaceuticals | P2/3 | BB |
| Cintredekin Besudotox | INSYS Therapeutics Inc | P1/2 | BB |
| Carboplatin | Oliver Jonas | P2 | BB |
| Temsirolimus | Andrew B Lassman, MD | P1/2 | B |
| Trametinib | National Cancer Institute (NCI) | P4 | B |
| Valproic Acid | University of Göttingen | P3 | B |
+42 more in the Anaplastic Astrocytoma cohort
Other indications for Trabedersen
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2 | CCC · 48 |
| Lung Cancer | — | P2 | CC · 43 |
| Glioblastoma | — | P3 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trabedersen in Anaplastic Astrocytoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trabedersen-anaplastic-astrocytoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →